Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VIVACAINE vs MARCAINE HYDROCHLORIDE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
VIVACAINE is a local anesthetic that blocks the generation and conduction of nerve impulses by decreasing sodium ion permeability across the neuronal membrane.
Bupivacaine is an amide-type local anesthetic that blocks voltage-gated sodium channels in nerve cell membranes, reversibly inhibiting nerve impulse propagation, particularly in sensory fibers.
Local or regional anesthesia for surgical procedures,Dental procedures,Pain management in minor surgeries
Local infiltration anesthesia,Peripheral nerve block,Central neuraxial block (epidural, spinal),Dental procedures,Postoperative pain management,Obstetrical anesthesia (epidural)
5-10 m L of 1% solution (50-100 mg) via submucosal infiltration or nerve block; maximum 500 mg per procedure.
Adults: 0.5% solution infiltrated up to 175 mg (35 m L) for minor procedures; for major procedures, up to 225 mg (45 m L) with epinephrine. Repeat doses at 3-hour intervals. Maximum dose 400 mg with epinephrine.
Terminal elimination half-life: 6–8 hours in healthy adults. In patients with hepatic impairment, half-life may be prolonged up to 12–15 hours; in severe renal impairment (Cr Cl <30 m L/min), half-life may extend to 10–12 hours.
Terminal elimination half-life is approximately 2.5 to 3.5 hours in adults; may be prolonged in neonates (8-12 hours) or patients with hepatic impairment.
No adjustment required for mild to moderate impairment; contraindicated in end-stage renal disease (e GFR <15 m L/min).
No specific dose adjustment recommended for GFR > 30 m L/min. For GFR < 30 m L/min, reduce dose by 25-50% and monitor for toxicity.
Not available
First trimester: Limited human data; animal studies show increased risk of cardiac malformations at high doses. Second/third trimester: Associated with fetal bradycardia and decreased beat-to-beat variability; use only if clearly needed.
Bupivacaine hydrochloride is classified as FDA Pregnancy Category C. In the first trimester, there is a potential risk of teratogenicity based on animal studies showing adverse effects at high doses, but no well-controlled human studies exist. During the second and third trimesters, use may cause fetal bradycardia, acidosis, and central nervous system depression due to placental transfer. Risk of fetal hypoxia and bradycardia increases with higher doses or inadvertent intravascular injection. Paracervical block in early pregnancy is associated with fetal bradycardia.
Vivacaine (bupivacaine liposome) is a long-acting local anesthetic; for surgical site infiltration, do not admix with other local anesthetics as it may alter particle structure. Use a 25G or larger needle for administration to avoid needle clogging. Onset is delayed (up to 30 min) compared to standard bupivacaine; plan accordingly. Do not exceed 266 mg (20 m L of 1.3% formulation) in adults. Avoid concurrent use with Class I antiarrhythmics (e.g., lidocaine) due to additive cardiotoxicity risk. Monitor for signs of local anesthetic systemic toxicity (LAST) up to 48 hours post-administration.
Bupivacaine is highly protein-bound and has a slow dissociation from sodium channels, resulting in prolonged duration of action. Use with caution in hepatic impairment due to extensive liver metabolism. Avoid intravenous regional anesthesia (Bier block) as it can cause severe cardiac toxicity. Maximum single dose for infiltration is 175 mg (without epinephrine) or 225 mg (with epinephrine).
No interactions on record
No interactions on record
VIVACAINE and MARCAINE HYDROCHLORIDE are distinct pharmacological agents. VIVACAINE belongs to the Local Anesthetic class and is primarily used for Local or regional anesthesia for surgical proceduresDental proceduresPain management in minor surgeries. MARCAINE HYDROCHLORIDE belongs to the Local Anesthetic class and is primarily used for Local infiltration anesthesiaPeripheral nerve blockCentral neuraxial block (epidural, spinal)Dental proceduresPostoperative pain managementObstetrical anesthesia (epidural). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. VIVACAINE carries a safety status of Category C, whereas MARCAINE HYDROCHLORIDE safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily hepatic via ester hydrolysis by pseudocholinesterase
Primarily hepatic via CYP1A2 and CYP3A4; major metabolite is pipecolylxylidine (PPX).
Renal excretion of unchanged drug and metabolites accounts for approximately 85–90% of elimination, with about 10–15% excreted in feces via biliary clearance. Less than 2% of the dose is recovered unchanged in urine; the remainder is as glucuronide conjugates and other metabolites.
Primarily hepatic metabolism; less than 5% excreted unchanged in urine. Metabolites are excreted renally, with a small amount in feces via biliary elimination.
Approximately 92–95% bound to plasma proteins, primarily albumin (85%) and alpha-1-acid glycoprotein (10%).
Approximately 95% bound primarily to alpha-1-acid glycoprotein and albumin.
Volume of distribution: 1.5–2.5 L/kg, indicating extensive tissue distribution. Higher Vd in elderly and patients with heart failure (up to 3.5 L/kg).
1.3 L/kg; indicates extensive tissue distribution, characteristic of lipophilic amide local anesthetics.
Oral: 35–45% (first-pass metabolism; range 25–50%). Intramuscular: 85–95%. Subcutaneous: 80–90%. Rectal: 50–65%.
Not applicable for injection; negligible oral bioavailability due to extensive first-pass metabolism. For infiltration or nerve block, bioavailability is 100% at the site of administration.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: contraindicated.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 40%. Child-Pugh C: Contraindicated or use with extreme caution and 50% dose reduction.
1-2 mg/kg via infiltration, not to exceed 4.5 mg/kg total; maximum 300 mg per procedure.
Weight-based: 0.5% solution, maximum 2 mg/kg for infiltration; for regional blocks, 1.5 mg/kg. With epinephrine, up to 3 mg/kg. Use lowest effective dose.
Reduce dose by 20% due to decreased clearance; maximum 400 mg per procedure.
Elderly: Reduce dose by 20-30% due to age-related decreases in clearance; use lower concentrations (0.25%) and minimal volumes. Monitor for CNS and cardiac effects.
Risk of cardiac arrest and seizures following unintentional intravascular injection; use with extreme caution when administering large doses. Avoid rapid injection. Resuscitative equipment and personnel trained in advanced cardiac life support must be immediately available.
Risk of systemic toxicity (CNS and cardiovascular), particularly with high doses or accidental intravascular injection. Use with caution in patients with hepatic impairment, cardiac disease, or myasthenia gravis. Monitor for signs of methemoglobinemia (rare). Avoid use in patients with severe hypotension or shock.
Known hypersensitivity to bupivacaine or other amide-type anesthetics, severe pre-existing hypotension, bacteremia, thrombocytopenia, coagulopathy (for neuraxial use), obstetrical paracervical block anesthesia (due to fetal bradycardia).
No clinically significant food interactions known. Avoid excessive grapefruit juice intake (may increase bupivacaine levels theoretically, though liposomal formulation may be less affected). Maintain adequate hydration after surgery.
No known food interactions.
Excreted in breast milk in low amounts (M/P ratio ~0.5). Considered compatible with breastfeeding; monitor infant for bradycardia and irritability.
Bupivacaine is excreted into breast milk in low concentrations (estimated M/P ratio approximately 0.2–0.4). The relative infant dose is estimated at <2% of maternal weight-adjusted dose, considered compatible with breastfeeding. However, caution is advised if the infant has reduced metabolic capacity or if repeated high maternal doses are used. Monitor infant for signs of local anesthetic toxicity (e.g., lethargy, poor feeding).
Increased plasma volume may require higher doses for efficacy; but reduced protein binding may increase free drug concentration. Use lowest effective dose; avoid paracervical block; reduce total dose by 20-30% in late pregnancy due to enhanced sensitivity.
Pregnancy may increase clearance and volume of distribution, potentially requiring higher doses for epidural anesthesia. However, the risk of toxicity and fetal exposure limits dose increases; use lowest effective dose. Epidural doses may need reduction due to increased sensitivity to local anesthetics and decreased protein binding (increased free fraction). Fractionated dosing and test doses are recommended. No specific dose adjustment guidelines; clinical judgment based on maternal response and fetal status.
Vivacaine is a long-acting numbing medicine that provides pain relief for up to 72 hours after surgery.,Do not drive or operate heavy machinery for at least 24 hours after receiving Vivacaine, or until effects of any sedation have worn off.,If you experience ringing in ears, metallic taste, dizziness, or numbness of the tongue, seek emergency medical attention immediately.,Do not apply additional local anesthetics or ice packs directly over the injection site without consulting your doctor.,Report any signs of infection at the injection site (redness, swelling, warmth) or persistent pain beyond the expected duration.
Report any numbness or weakness that persists longer than expected.,Seek immediate medical attention if you experience ringing in ears, metallic taste, or dizziness.,Avoid driving or operating machinery until full sensation and motor function return.,Inform your doctor if you have liver disease or are taking antiarrhythmic drugs.